SCHEMBL6786238

SCHEMBL6786238

COC(=O)c1cc(-n2nc(C)cc2C)ccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
MAPT P10636 8/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.48
TSHR P16473 3/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALOX15 P16050 1/20 0.48
TDP1 Q9NUW8 1/20 0.45
TERT O14746 1/20 0.44
POLB P06746 3/20 0.44
MAPK1 P28482 3/20 0.44
RAB9A P51151 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
MAPK10 P53779 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786036 0.80 SIRT6 (0.57) ALDH1A1L3MBTL1MAPTHPGDGAA
SCHEMBL9197356 0.80 SMN1; SMN2 (0.48) ALDH1A1L3MBTL1MAPTHPGDTDP1
SCHEMBL3369502 0.73 MAPT (0.48) ALDH1A1MAPTHPGDHSD17B10TSHR
SCHEMBL2668167 0.73 ALDH1A1 (0.43) ALDH1A1L3MBTL1MAPTHPGDTSHR
SCHEMBL1784439 0.72 ALDH1A1 (0.77) ALDH1A1L3MBTL1MAPTHPGDHSD17B10
SCHEMBL6839351 0.72 MAPT (0.50) ALDH1A1L3MBTL1MAPTHPGDTSHR
SCHEMBL20509930 0.71 IP6K1 (0.68) ALDH1A1L3MBTL1MAPTHPGDHSD17B10
SCHEMBL13519044 0.71 P2RY12 (0.48) ALDH1A1MAPTHPGDHSD17B10TSHR
SCHEMBL1129416 0.71 ALDH1A1 (0.64) ALDH1A1L3MBTL1MAPTHPGDHSD17B10
SCHEMBL40467 0.70 IP6K1 (0.66) ALDH1A1L3MBTL1MAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 ALDH1A1 102/4885L3MBTL1 2283/4885MAPT 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.